Equities

StemRIM Inc

4599:TYO

StemRIM Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)453.00
  • Today's Change5.00 / 1.12%
  • Shares traded135.40k
  • 1 Year change-38.03%
  • Beta1.8227
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.

  • Revenue in JPY (TTM)0.00
  • Net income in JPY-2.02bn
  • Incorporated2006
  • Employees44.00
  • Location
    StemRIM Inc3F, Saito Bio-Incubator, 7-7-15, SaitoIBARAKI-SHI 567-0085JapanJPN
  • Phone+81 726487152
  • Websitehttps://stemrim.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Stella Pharma Corp269.49m-759.81m18.45bn44.00--6.55--68.45-24.30-24.308.6282.710.05940.05173.986,124,796.00-16.73-22.50-17.64-24.8380.37---281.94-488.6515.60-943.380.2481--17.65--1.94---5.87--
TAIKO PHARMACEUTICAL CO LTD6.49bn-2.33bn20.31bn208.00--2.49--3.13-46.91-46.91130.40160.860.44741.913.7131,211,540.00-16.07---19.68--49.37---35.92--2.95--0.2437--21.43--26.23------
Fuso Pharmaceutical Industries Ltd56.52bn1.53bn20.82bn1.31k12.300.50525.520.3684179.11179.116,607.604,361.000.74543.082.3543,245,600.002.021.913.503.0925.6726.922.712.690.939336.590.276741.108.613.76-14.219.029.13-2.64
Astena Holdings Co Ltd53.22bn2.10bn21.07bn1.40k9.710.7164.840.395852.9252.921,343.58717.870.81053.422.7337,904,980.003.182.495.774.4433.1825.333.932.320.889--0.343944.924.73-2.85100.61-3.8538.5411.38
CanBas Co Ltd (Parent)0.00-1.21bn23.93bn12.00--9.85-----67.63-67.630.00129.880.00-------53.54-62.25-56.62-70.91--------25.09----------2.77------
StemRIM Inc0.00-2.02bn27.56bn44.00--3.10-----32.98-32.980.00144.570.00-------20.44-8.34-20.74-8.49-------68.74131.03-11,344.72-----100.00---1,301.17---4.35--
CellSeed Inc199.47m-957.04m27.68bn35.00--12.62--138.75-30.72-30.726.4063.290.08921.657.915,699,172.00-42.79-49.69-46.02-54.5555.3863.66-479.79-428.6216.42-5,460.760.0651--50.39-28.62-11.43--80.73--
Fuji Pharma Co Ltd44.56bn6.36bn31.41bn1.62k4.850.68633.190.7049261.79261.791,833.311,849.150.51561.403.1527,490,440.007.364.1011.635.5839.2842.4114.287.550.6276--0.391231.1715.421.5227.410.370919.045.73
Daito Pharmaceutical Co Ltd46.90bn3.30bn34.18bn1.07k10.600.65415.000.7289210.18210.182,988.663,404.720.63261.892.9643,827,100.004.296.275.588.2420.9822.656.788.471.11--0.14319.593.982.66-8.47-1.2711.3711.67
Data as of Sep 20 2024. Currency figures normalised to StemRIM Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

2.34%Per cent of shares held by top holders
HolderShares% Held
Schroder Investment Management (Japan) Ltd.as of 31 May 2024537.70k0.87%
Schroder Investment Management Ltd.as of 31 Dec 2023342.10k0.56%
Daiwa Asset Management Co. Ltd.as of 30 Jun 2024279.90k0.46%
Simplex Asset Management Co., Ltd.as of 05 Sep 2024165.40k0.27%
Mitsubishi UFJ Asset Management Co., Ltd.as of 31 Dec 202349.90k0.08%
Meiji Yasuda Asset Management Co. Ltd.as of 29 Nov 202235.00k0.06%
SSgA Funds Management, Inc.as of 05 Sep 202419.30k0.03%
Amundi Japan Ltd.as of 11 Sep 20233.70k0.01%
Connor, Clark & Lunn Investment Management Ltd.as of 31 Dec 20232.80k0.01%
LGT Capital Partners AG (Investment Management)as of 31 May 20242.50k0.00%
More ▼
Data from 31 May 2024 - 12 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.